An Update on the Molecular Genetics of Hepatocellular Carcinoma

Seminars in Liver Disease

Volumn 24, Issue 1, 2004, Pages 77-88

  Suriawinata, Arief ^b   Xu, Ruliang ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Gene expression profile; Hepatocarcinogenesis; Hepatocellular carcinoma; Molecular genetics

Indexed keywords

PROTEIN P53; RETINOBLASTOMA PROTEIN; WNT PROTEIN;

CARCINOGENESIS; CHROMOSOME ABERRATION; DNA MICROARRAY; EARLY DIAGNOSIS; GENE EXPRESSION; GENE EXPRESSION PROFILING; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HETEROZYGOSITY LOSS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALIGNANT TRANSFORMATION; METASTASIS; MICROSATELLITE INSTABILITY; MOLECULAR GENETICS; MUTATION; PRECANCER; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR;

AFLATOXINS; CARCINOMA, HEPATOCELLULAR; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION PROFILING; HEPATITIS B; HEPATITIS C; HUMANS; LIVER NEOPLASMS; METAL METABOLISM, INBORN ERRORS; PRECANCEROUS CONDITIONS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 1942519270     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-823102     Document Type: Review

References (153)

1. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-750
2. Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis 1999;19:271-285
3. Tsutsumi T, Suzuki T, Moriya K, et al. Alteration of intrahepatic cytokine expression and AP-1 activation in transgenic mice expressing hepatitis C virus core protein. Virology 2002;304:415-424
4. Durr R, Caselmann WH. Carcinogenesis of primary liver malignancies. Langenbecks Arch Surg 2000;385:154-161
5. El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 2002;36:S74-S83
6. Sun M, Eshleman JR, Ferrell LD, et al. An early lesion in hepatic carcinogenesis: loss of heterozygosity in human cirrhotic livers and dysplastic nodules at the 1p36-p34 region. Hepatology 2001;33:1415-1424
7. Theise ND, Schwartz M, Miller C, Thung SN. Macroregenerative nodules and hepatocellular carcinoma in forty-four sequential adult liver explants with cirrhosis. Hepatology 1992;16:949-955
8. Orsatti G, Theise ND, Thung SN, Paronetto F. DNA image cytometric analysis of macroregenerative nodules (adenomatous hyperplasia) of the liver: evidence in support of their preneoplastic nature. Hepatology 1993;17:621-627
9. Takayama T, Makuuchi M, Hirohashi S, et al. Malignant transformation of adenomatous hyperplasia to hepatocellular carcinoma. Lancet 1990;336:1150-1153
10. Edamoto Y, Hara A, Biernat W, et al. Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis. Int J Cancer 2003;106:334-341
11. Wang XW, Hussain SP, Huo TI, et al. Molecular pathogenesis of human hepatocellular carcinoma. Toxicology 2002;181-182:43-47
12. Koike K, Tsutsumi T, Fujie H, et al. Molecular mechanism of viral hepatocarcinogenesis. Oncology 2002;62(Suppl 1): 29-37
13. Kim JW, Wang XW. Gene expression profiling of preneoplastic liver disease and liver cancer: a new era for improved early detection and treatment of these deadly diseases? Carcinogenesis 2003;24:363-369
14. Staib F, Hussain SP, Hofseth LJ, et al. TP53 and liver carcinogenesis. Hum Mutat 2003;21:201-216
15. Paterlini-Brechot P, Vona G, Brechot C. Circulating tumorous cells in patients with hepatocellular carcinoma. Clinical impact and future directions. Semin Cancer Biol 2000;10:241-249
16. Gozuacik D, Murakami Y, Saigo K, et al. Identification of human cancer-related genes by naturally occurring Hepatitis B Virus DNA tagging. Oncogene 2001;20:6233-6240
17. Nakamoto Y, Guidotti LG, Kuhlen CV, et al. Immune pathogenesis of hepatocellular carcinoma. J Exp Med 1998;188:341-350
18. Chisari FV, Ferrari C. Hepatitis B virus immunopathology. Springer Semin Immunopathol 1995;17:261-281
19. Chisari FV, Filippi P, Buras J, et al. Structural and pathological effects of synthesis of hepatitis B virus large envelope polypeptide in transgenic mice. Proc Natl Acad Sci USA 1987;84:6909-6913
20. Murakami S. Hepatitis B virus X protein: a multifunctional viral regulator. J Gastroenterol 2001;36:651-660
21. Caselmann WH. Trans-activation of cellular genes by hepatitis B virus proteins: a possible mechanism of hepatocarcinogenesis. Adv Virus Res 1996;47:253-302
22. Qadri I, Maguire HF, Siddiqui A. Hepatitis B virus transactivator protein X interacts with the TATA-binding protein. Proc Natl Acad Sci USA 1995;92:1003-1007
23. Haviv I, Shamay M, Doitsh G, Shaul Y. Hepatitis B virus pX targets TFIIB in transcription coactivation. Mol Cell Biol 1998;18:1562-1569
24. Natoli G, Avantaggiati ML, Chirillo P, et al. Ras- and Raf-dependent activation of c-jun transcriptional activity by the hepatitis B virus transactivator pX. Oncogene 1994;9:2837-2843
25. Benn J, Schneider RJ. Hepatitis B virus HBx protein activates Ras-GTP complex formation and establishes a Ras, Raf, MAP kinase signaling cascade. Proc Natl Acad Sci USA 1994;91:10350-10354
26. Su F, Schneider RJ. Hepatitis B virus HBx protein activates transcription factor NF-kappaB by acting on multiple cytoplasmic inhibitors of rel-related proteins. J Virol 1996;70:4558-4566
27. Terradillos O, Billet O, Renard CA, et al. The hepatitis B virus X gene potentiates c-myc-induced liver oncogenesis in transgenic mice. Oncogene 1997;14:395-404
28. Chirillo P, Pagano S, Natoli G, et al. The hepatitis B virus X gene induces p53-mediated programmed cell death. Proc Natl Acad Sci USA 1997;94:8162-8167
29. Elmore LW, Hancock AR, Chang SF, et al. Hepatitis B virus X protein and p53 tumor suppressor interactions in the modulation of apoptosis. Proc Natl Acad Sci USA 1997;94:14707-14712
30. Hu Z, Zhang Z, Doo E, et al. Hepatitis B virus X protein is both a substrate and a potential inhibitor of the proteasome complex. J Virol 1999;73:7231-7240
31. Lee DK, Park SH, Yi Y, et al. The hepatitis B virus encoded oncoprotein pX amplifies TGF-beta family signaling through direct interaction with Smad4: potential mechanism of hepatitis B virus-induced liver fibrosis. Genes Dev 2001;15:455-466
32. Sirma H, Giannini C, Poussin K, et al. Hepatitis B virus X mutants, present in hepatocellular carcinoma tissue abrogate both the antiproliferative and transactivation effects of HBx. Oncogene 1999;18:4848-4859
33. Su Q, Schroder CH, Hofmann WJ, et al. Expression of hepatitis B virus X protein in HBV-infected human livers and hepatocellular carcinomas. Hepatology 1998;27:1109-1120
34. Gottlob K, Pagano S, Levrero M, Graessmann A. Hepatitis B virus X protein transcription activation domains are neither required nor sufficient for cell transformation. Cancer Res 1998;58:3566-3570
35. Wu CG, Salvay DM, Forgues M, et al. Distinctive gene expression profiles associated with Hepatitis B virus x protein. Oncogene 2001;20:3674-3682
36. Wu CG, Forgues M, Siddique S, et al. SAGE transcript profiles of normal primary human hepatocytes expressing oncogenic hepatitis B virus X protein. FASEB J 2002;16: 1665-1667
37. Kasai Y, Takeda S, Takagi H. Pathogenesis of hepatocellular carcinoma: a review from the viewpoint of molecular analysis. Semin Surg Oncol 1996;12:155-159
38. Chen CM, You LR, Hwang LH, Lee YH. Direct interaction of hepatitis C virus core protein with the cellular lymphotoxin-beta receptor modulates the signal pathway of the lymphotoxin-beta receptor. J Virol 1997;71:9417-9426
39. Xu XR, Huang J, Xu ZG, et al. Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver. Proc Natl Acad Sci USA 2001;98:15089-15094
40. Block TM, Mehta AS, Fimmel CJ, Jordan R. Molecular viral oncology of hepatocellular carcinoma. Oncogene 2003;22:5093-5107
41. Moriya K, Fujie H, Shintani Y, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998;4:1065-1067
42. Gale M Jr, Blakely CM, Kwieciszewski B, et al. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol Cell Biol 1998;18:5208-5218
43. Kaufman RJ. Double-stranded RNA-activated protein kinase mediates virus-induced apoptosis: a new role for an old actor. Proc Natl Acad Sci USA 1999;96:11693-11695
44. Gale M Jr, Kwieciszewski B, Dossett M, et al. Antiapoptotic and oncogenic potentials of hepatitis C virus are linked to interferon resistance by viral repression of the PKR protein kinase. J Virol 1999;73:6506-6516
45. Mottola G, Cardinali G, Ceccacci A, et al. Hepatitis C virus nonstructural proteins are localized in a modified endoplasmic reticulum of cells expressing viral subgenomic replicons. Virology 2002;293:31-43
46. Newberne PM. Chemical carcinogenesis: mycotoxins and other chemicals to which humans are exposed. Semin Liver Dis 1984;4:122-135
47. Henry SH, Bosch FX, Bowers JC. Aflatoxin, hepatitis and worldwide liver cancer risks. Adv Exp Med Biol 2002;504: 229-233
48. Smela ME, Currier SS, Bailey EA, Essigmann JM. The chemistry and biology of aflatoxin B(1): from mutational spectrometry to carcinogenesis. Carcinogenesis 2001;22:535-545
49. Smela ME, Hamm ML, Henderson PT, et al. The aflatoxin B(1) formamidopyrimidine adduct plays a major role in causing the types of mutations observed in human hepatocellular carcinoma. Proc Natl Acad Sci USA 2002;99:6655-6660
50. Kress S, Jahn UR, Buchmann A, et al. p53 Mutations in human hepatocellular carcinomas from Germany. Cancer Res 1992;52:3220-3223
51. Ozturk M. p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet 1991;338:1356-1359
52. Aguilar F, Harris CC, Sun T, et al. Geographic variation of p53 mutational profile in nonmalignant human liver. Science 1994;264:1317-1319
53. Li Y, Su JJ, Qin LL, et al. Synergistic effect of hepatitis B virus and aflatoxin B1 in hepatocarcinogenesis in tree shrews. Ann Acad Med Singapore 1999;28:67-71
54. Buss P, Caviezel M, Lutz WK. Linear dose-response relationship for DNA adducts in rat liver from chronic exposure to aflatoxin B1. Carcinogenesis 1990;11:2133-2135
55. Guengerich FP, Johnson WW, Ueng YF, et al. Involvement of cytochrome P450, glutathione S-transferase, and epoxide hydrolase in the metabolism of aflatoxin B1 and relevance to risk of human liver cancer. Environ Health Perspect 1996;104 (Suppl 3):557-562
56. Hussain SP, Raja K, Amstad PA, et al. Increased p53 mutation load in nontumorous human liver of wilson disease and hemochromatosis: oxyradical overload diseases. Proc Natl Acad Sci USA 2000;97:12770-12775
57. Niederau C, Fischer R, Sonnenberg A, et al. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med 1985;313:1256-1262
58. Deugnier Y, Turlin B. Iron and hepatocellular carcinoma. J Gastroenterol Hepatol 2001;16:491-494
59. Boige V, Castera L, de Roux N, et al. Lack of association between HFE gene mutations and hepatocellular carcinoma in patients with cirrhosis. Gut 2003;52:1178-1181
60. Cauza E, Peck-Radosavljevic M, Ulrich-Pur H, et al. Mutations of the HFE gene in patients with hepatocellular carcinoma. Am J Gastroenterol 2003;98:442-447
61. Vautier G, Bomford AB, Portmann BC, et al. p53 mutations in british patients with hepatocellular carcinoma: clustering in genetic hemochromatosis. Gastroenterology 1999;117: 154-160
62. Narayanan VS, Fitch CA, Levenson CW. Tumor suppressor protein p53 mRNA and subcellular localization are altered by changes in cellular copper in human Hep G2 cells. J Nutr 2001;131:1427-1432
63. Wang Y, Wu MC, Sham JS, et al. Different expression of hepatitis B surface antigen between hepatocellular carcinoma and its surrounding liver tissue, studied using a tissue microarray. J Pathol 2002;197:610-616
64. Theise ND. Macroregenerative (dysplastic) nodules and hepatocarcinogenesis: theoretical and clinical considerations. Semin Liver Dis 1995;15:360-371
65. Hytiroglou P, Theise ND. Differential diagnosis of hepatocellular nodular lesions. Semin Diagn Pathol 1998;15:285-299
66. Thung SN, Hytiroglou P, Fiel I, Theise N. Preneoplastic lesions in chronic hepatitis C. Princess Takamatsu Symp 1995;25:171-178
67. Hytiroglou P, Theise ND, Schwartz M, et al. Macroregenerative nodules in a series of adult cirrhotic liver explants: issues of classification and nomenclature. Hepatology 1995;21:703-708
68. Aihara T, Noguchi S, Sasaki Y, et al. Clonal analysis of precancerous lesion of hepatocellular carcinoma. Gastroenterology 1996;111:455-461
69. Okuda T, Wakasa K, Kubo S, et al. Clonal analysis of hepatocellular carcinoma and dysplastic nodule by methylation pattern of X-chromosome-linked human androgen receptor gene. Cancer Lett 2001;164:91-96
70. Paradis V, Laurendeau I, Vidaud M, Bedossa P. Clonal analysis of macronodules in cirrhosis. Hepatology 1998; 28:953-958
71. Terracciano L, Tornillo L. Cytogenetic alterations in liver cell tumors as detected by comparative genomic hybridization. Pathologica 2003;95:71-82
72. Riegler JL. Preneoplastic conditions of the liver. Semin Gastrointest Dis 1996;7:74-87
73. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002;31:339-346
74. Paradis V, Dargere D, Bonvoust F, et al. Clonal analysis of micronodules in virus C-induced liver cirrhosis using laser capture microdissection (LCM) and HUMARA assay. Lab Invest 2000;80:1553-1559
75. Kanai Y, Ushijima S, Tsuda H, et al. Aberrant DNA methylation precedes loss of heterozygosity on chromosome 16 in chronic hepatitis and liver cirrhosis. Cancer Lett 2000;148:73-80
76. Lin CH, Hsieh SY, Sheen IS, et al. Genome-wide hypomethylation in hepatocellular carcinogenesis. Cancer Res 2001;61:4238-4243
77. Shen L, Fang J, Qiu D, et al. Correlation between DNA methylation and pathological changes in human hepatocellular carcinoma. Hepatogastroenterology 1998;45:1753-1759
78. Shim YH, Yoon GS, Choi HJ, et al. p16 Hypermethylation in the early stage of hepatitis B virus-associated hepatocarcinogenesis. Cancer Lett 2003;190:213-219
79. Saito Y, Kanai Y, Sakamoto M, et al. Expression of mRNA for DNA methyltransferases and methyl-CpG-binding proteins and DNA methylation status on CpG islands and pericentromeric satellite regions during human hepatocarcinogenesis. Hepatology 2001;33:561-568
80. Karachristos A, Liloglou T, Field JK, et al. Microsatellite instability and p53 mutations in hepatocellular carcinoma. Mol Cell Biol Res Commun 1999;2:155-161
81. Piao Z, Kim H, Malkhosyan S, Park C. Frequent chromosomal instability but no microsatellite instability in hepatocellular carcinomas. Int J Oncol 2000;17:507-512
82. Nishida N, Nishimura T, Ito T, et al. Chromosomal instability and human hepatocarcinogenesis. Histol Histopathol 2003;18:897-909
83. Nagai H, Emi M, Terada Y, et al. DNA alterations during multi-step development of human hepatocellular carcinomas revealed by laser capture microdissection. Hepatol Res 2003;26:199-208
84. Kahng YS, Lee YS, Kim BK, et al. Loss of heterozygosity of chromosome 8p and 11p in the dysplastic nodule and hepatocellular carcinoma. J Gastroenterol Hepatol 2003; 18:430-436
85. Maggioni M, Coggi G, Cassani B, et al. Molecular changes in hepatocellular dysplastic nodules on microdissected liver biopsies. Hepatology 2000;32:942-946
86. Anders RA, Yerian LM, Tretiakova M, et al. cDNA microarray analysis of macroregenerative and dysplastic nodules in end-stage hepatitis C virus-induced cirrhosis. Am J Pathol 2003;162:991-1000
87. Kim JW, Sime J, Forgues M, et al. Molecular characterization of preneoplastic liver diseases by cDNA microarray. 93rd meeting of the American Association for Cancer Research, April 6-10, 2002, San Francisco, CA. Proc Am Assoc Cancer Res 2002;43:461-462
88. Roncalli M, Bianchi P, Grimaldi GC, et al. Fractional allelic loss in non-end-stage cirrhosis: correlations with hepatocellular carcinoma development during follow-up. Hepatology 2000;31:846-850
89. Wilkens L, Bredt M, Flemming P, et al. Comparative genomic hybridization (CGH) and fluorescence in situ hybridization (FISH) in the diagnosis of hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 2002;9:304-311
90. Simon D, Knowles BB, Weith A. Abnormalities of chromosome 1 and loss of heterozygosity on 1p in primary hepatomas. Oncogene 1991;6:765-770
91. Wilkens L, Bredt M, Flemming A, et al. Detection of chromosomal aberrations in well-differentiated hepatocellular carcinoma by bright-field in situ hybridization. Mod Pathol 2002;15:470-475
92. Buendia MA. Genetics of hepatocellular carcinoma. Semin Cancer Biol 2000;10:185-200
93. Nagai H, Pineau P, Tiollais P, et al. Comprehensive allelotyping of human hepatocellular carcinoma. Oncogene 1997;14:2927-2933.
94. Buendia MA. Genetic alterations in hepatoblastoma and hepatocellular carcinoma: common and distinctive aspects. Med Pediatr Oncol 2002;39:530-535
95. Oka Y, Waterland RA, Killian JK, et al. M6P/IGF2R tumor suppressor gene mutated in hepatocellular carcinomas in Japan. Hepatology 2002;35:1153-1163
96. Nishimura T, Nishida N, Itoh T, et al. Comprehensive allelotyping of well-differentiated human hepatocellular carcinoma with semiquantitative determination of chromosomal gain or loss. Genes Chromosomes Cancer 2002;35: 329-339
97. De Souza AT, Hankins GR, Washington MK, et al. M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. Nat Genet 1995;11:447-449
98. Murakami Y, Hayashi K, Hirohashi S, Sekiya T. Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas. Cancer Res 1991;51: 5520-5525
99. Satoh S, Daigo Y, Furukawa Y, et al. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet 2000; 24:245-250
100. Kuroki T, Fujiwara Y, Tsuchiya E, et al. Accumulation of genetic changes during development and progression of hepatocellular carcinoma: loss of heterozygosity of chromosome arm 1p occurs at an early stage of hepatocarcinogenesis. Genes Chromosomes Cancer 1995;13:163-167
101. Lin YW, Sheu JC, Huang GT, et al. Chromosomal abnormality in hepatocellular carcinoma by comparative genomic hybridisation in Taiwan. Eur J Cancer 1999;35: 652-658
102. Tamura S, Nakamori S, Kuroki T, et al. Association of cumulative allelic losses with tumor aggressiveness in hepatocellular carcinoma. J Hepatol 1997;27:669-676
103. Guan XY, Fang Y, Sham J, et al. Recurrent chromosome alterations in hepatocellular carcinoma detected by comparative genomic hybridization. Genes Chromosomes Cancer 2001;30:110-116
104. Chang J, Kim NG, Piao Z, et al. Assessment of chromosomal losses and gains in hepatocellular carcinoma. Cancer Lett 2002;182:193-202
105. Chen YJ, Yeh SH, Chen JT, et al. Chromosomal changes and clonality relationship between primary and recurrent hepatocellular carcinoma. Gastroenterology 2000;119:431-440
106. Zhang LH, Qin LX, Ma ZC, et al. Allelic imbalance regions on chromosomes 8p, 17p and 19p related to metastasis of hepatocellular carcinoma: comparison between matched primary and metastatic lesions in 22 patients by genome-wide microsatellite analysis. J Cancer Res Clin Oncol 2003; 129:279-286
107. Wilkens L, Bredt M, Flemming P, et al. Differentiation of multicentric origin from intra-organ metastatic spread of hepatocellular carcinomas by comparative genomic hybridization. J Pathol 2000;192:43-51
108. Kusano N, Shiraishi K, Kubo K, et al. Genetic aberrations detected by comparative genomic hybridization in hepatocellular carcinomas: their relationship to clinicopathological features. Hepatology 1999;29:1858-1862
109. Marchio A, Pineau P, Meddeb M, et al. Distinct chromosomal abnormality pattern in primary liver cancer of non-B, non-C patients. Oncogene 2000;19:3733-3738
110. Huang XH, Sun LH, Lu DD, et al. Codon 249 mutation in exon 7 of p53 gene in plasma DNA: maybe a new early diagnostic marker of hepatocellular carcinoma in Qidong risk area, China. World J Gastroenterol 2003;9:692-695
111. Kirk GD, Camus-Randon AM, Mendy M, et al. Ser-249 p53 mutations in plasma DNA of patients with hepatocellular carcinoma from The Gambia. J Natl Cancer Inst 2000;92:148-153
112. Chung TW, Lee YC, Ko JH, Kim CH. Hepatitis B virus X protein modulates the expression of PTEN by inhibiting the function of p53, a transcriptional activator in liver cells. Cancer Res 2003;63:3453-3458
113. Hsia CC, Di Bisceglie AM, Kleiner DE Jr, et al. RB tumor suppressor gene expression in hepatocellular carcinomas from patients infected with the hepatitis B virus. J Med Virol 1994;44:67-73
114. Matsuda Y, Ichida T, Genda T, et al. Loss of p16 contributes to p27 sequestration by cyclin D(1)-cyclin-dependent kinase 4 complexes and poor prognosis in hepatocellular carcinoma. Clin Cancer Res 2003;9:3389-3396
115. Ng IO, Liang ZD, Cao L, Lee TK. DLC-1 is deleted in primary hepatocellular carcinoma and exerts inhibitory effects on the proliferation of hepatoma cell lines with deleted DLC-1. Cancer Res 2000;60:6581-6584
116. Wong IH, Lo YM, Yeo W, et al. Frequent p15 promoter methylation in tumor and peripheral blood from hepatocellular carcinoma patients. Clin Cancer Res 2000;6:3516-3521
117. Yoshikawa H, Matsubara K, Qian GS, et al. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet 2001;28:29-35
118. Tchou JC, Lin X, Freije D, et al. GSTP1 CpG island DNA hypermethylation in hepatocellular carcinomas. Int J Oncol 2000;16:663-676
119. Yang B, Guo M, Herman JG, Clark DP. Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am J Pathol 2003;163:1101-1107
120. Debuire B, Paterlini P, Pontisso P, et al. Analysis of the p53 gene in European hepatocellular carcinomas and hepatoblastomas. Oncogene 1993;8:2303-2306
121. Lin Y, Shi CY, Li B, et al. Tumour suppressor p53 and Rb genes in human hepatocellular carcinoma. Ann Acad Med Singapore 1996;25:22-30
122. Teramoto T, Satonaka K, Kitazawa S, et al. p53 gene abnormalities are closely related to hepatoviral infections and occur at a late stage of hepatocarcinogenesis. Cancer Res 1994;54:231-235
123. Oda T, Tsuda H, Sakamoto M, Hirohashi S. Different mutations of the p53 gene in nodule-in-nodule hepatocellular carcinoma as a evidence for multistage progression. Cancer Lett 1994;83:197-200
124. Tanaka S, Toh Y, Adachi E, et al. Tumor progression in hepatocellular carcinoma may be mediated by p53 mutation. Cancer Res 1993;53:2884-2887
125. Sheen IS, Jeng KS, Wu JY. Is p53 gene mutation an indicatior of the biological behaviors of recurrence of hepatocellular carcinoma? World J Gastroenterol 2003;9: 1202-1207
126. Jeng KS, Sheen IS, Chen BF, Wu JY. Is the p53 gene mutation of prognostic value in hepatocellular carcinoma after resection? Arch Surg 2000;135:1329-1333
127. Terradillos O, Pollicino T, Lecoeur H, et al. p53-independent apoptotic effects of the hepatitis B virus HBx protein in vivo and in vitro. Oncogene 1998;17:2115-2123
128. Chen GG, Merchant JL, Lai PB, et al. Mutation of p53 in recurrent hepatocellular carcinoma and its association with the expression of ZBP-89. Am J Pathol 2003;162:1823-1829
129. Kuroki T, Fujiwara Y, Nakamori S, et al. A Evidence for the presence of two tumour-suppressor genes for hepatocellular carcinoma on chromosome 13q. Br J Cancer 1995;72:383-385
130. Zhang X, Xu HJ, Murakami Y, et al. Deletions of chromosome 13q, mutations in Retinoblastoma 1, and retinoblastoma protein state in human hepatocellular carcinoma. Cancer Res 1994;54:4177-4182
131. Hui AM, Sakamoto M, Kanai Y, et al. Inactivation of p16INK4 in hepatocellular carcinoma. Hepatology 1996; 24:575-579
132. Jin M, Piao Z, Kim NG, et al. p16 is a major inactivation target in hepatocellular carcinoma. Cancer 2000;89:60-68
133. Liew CT, Li HM, Lo KW, et al. High frequency of p16INK4A gene alterations in hepatocellular carcinoma. Oncogene 1999;18:789-795
134. Hsu HC, Jeng YM, Mao TL, et al. Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am J Pathol 2000;157:763-770
135. Mao TL, Chu JS, Jeng YM, et al. Expression of mutant nuclear beta-catenin correlates with non-invasive hepatocellular carcinoma, absence of portal vein spread, and good prognosis. J Pathol 2001;193:95-101
136. Terris B, Pineau P, Bregeaud L, et al. Close correlation between beta-catenin gene alterations and nuclear accumulation of the protein in human hepatocellular carcinomas. Oncogene 1999;18:6583-6588
137. Wong CM, Fan ST, Ng IO. beta-Catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance. Cancer 2001;92:136-145
138. Nhieu JT, Renard CA, Wei Y, et al. Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation. Am J Pathol 1999;155:703-710
139. Kondo Y, Kanai Y, Sakamoto M, et al. Genetic instability and aberrant DNA methylation in chronic hepatitis and cirrhosis-A comprehensive study of loss of heterozygosity and microsatellite instability at 39 loci and DNA hypermethylation on 8 CpG islands in microdissected specimens from patients with hepatocellular carcinoma. Hepatology 2000;32:970-979
140. Yamamoto H, Itoh F, Fukushima H, et al. Infrequent widespread microsatellite instability in hepatocellular carcinomas. Int J Oncol 2000;16:543-547
141. Arcellana-Panlilio M, Robbins SM. Cutting-edge technology. I. Global gene expression profiling using DNA microarrays. Am J Physiol Gastrointest Liver Physiol 2002;282:G397-G402
142. Chung EJ, Sung YK, Farooq M, et al. Gene expression profile analysis in human hepatocellular carcinoma by cDNA microarray. Mol Cells 2002;14:382-387
143. Lau WY, Lai PB, Leung MF, et al. Differential gene expression of hepatocellular carcinoma using cDNA microarray analysis. Oncol Res 2000;12:59-69
144. Li Y, Tang R, Xu H, et al. Discovery and analysis of hepatocellular carcinoma genes using cDNA microarrays. J Cancer Res Clin Oncol 2002;128:369-379
145. Smith MW, Yue ZN, Geiss GK, et al. Identification of novel tumor markers in hepatitis C virus-associated hepatocellular carcinoma. Cancer Res 2003;63:859-864
146. Cheung ST, Chen X, Guan XY, et al. Identify metastasis-associated genes in hepatocellular carcinoma through donality delineation for multinodular tumor. Cancer Res 2002;62:4711-4721
147. Shirota Y, Kaneko S, Honda M, et al. Identification of differentially expressed genes in hepatocellular carcinoma with cDNA microarrays. Hepatology 2001;33:832-840
148. Okabe H, Satoh S, Kato T, et al. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res 2001; 61:2129-2137
149. Kondoh N, Wakatsuki T, Hada A, et al. Genetic and epigenetic events in human hepatocarcinogenesis. Int J Oncol 2001;18:1271-1278
150. Kondoh N, Shuda M, Tanaka K, et al. Enhanced expression of S8, L12, L23a, L27 and L30 ribosomal protein mRNAs in human hepatocellular carcinoma. Anticancer Res 2001;21:2429-2433
151. Yamashita T, Kaneko S, Hashimoto S, et al. Serial analysis of gene expression in chronic hepatitis C and hepatocellular carcinoma. Biochem Biophys Res Commun 2001;282:647-654
152. Li Y, Tang Y, Ye L, et al. Establishment of a hepatocellular carcinoma cell line with unique metastatic characteristics through in vivo selection and screening for metastasis-related genes through cDNA microarray. J Cancer Res Clin Oncol 2003;129:43-51
153. Iizuka N, Oka M, Yamada-Okabe H, et al. Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet 2003;361:923-929